Pharma News, 2024

AbbVie has announced accelerated approval from the US Food and Drug Administration (FDA) for EPKINLY (epcoritamab-bysp) to treat adult patients with relapsed or refractory follicular l...

MIRA Pharmaceuticals has announced promising preclinical results for its oral ketamine analog, Ketamir-2, showing it does not induce hyper-locomotor activity, a psychotic symptom common with tradition...

An open-label trial is currently assessing the safety, tolerability, and manufacturing feasibility of CT-0525.

Sona Nanotech Inc. is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University indicates that, beyond shrinking tum...

Radspherin is being evaluated in two studies to treat peritoneal carcinomatosis resulting from ovarian and colorectal cancer.

U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson’s Disease. This marks a significant ...

Fractyl Health, Inc., a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), presented new data from its preclinical Reju...

The Phase III HELIOS-B study met its primary and secondary endpoints in the monotherapy and overall study populations.

A vaccine to stop Alzheimer's disease, spearheaded by an Australian immunologist, is beginning human trials next week.

For more than a decade, argenx has sought to apply its novel antibody fragment treatment approach to various autoimmune diseases.

Significant progress has been made at Tufts University School of Engineering in the development of a small device, about the size of a vitamin pill, that can be swallowed and passed through the gastro...

Sanofi and Biovac have announced a partnership to establish the first African-based manufacturing capabilities for inactivated polio vaccines (IPV), marking a significant step towards regional...